StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Iovance Biotherapeutics cash

Cash and short-term investments held at the end of each period.

Iovance Biotherapeutics's cash was $297.67M at Jun 30, 2026. For fiscal 2025 it was $296.98M, down 10.0% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is $635.00M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$296.98M-10.0%
FY2024Dec 31, 2024$330.14M+18.0%
FY2023Dec 31, 2023$279.87M-41.5%
FY2022Dec 31, 2022$478.28M-6.3%
FY2021Dec 31, 2021$510.49M-19.6%
FY2020Dec 31, 2020$635.00M+103.2%
FY2019Dec 31, 2019$312.53M-19.1%
FY2018Dec 31, 2018$386.37M–
FY2017Dec 31, 2017$0-100.0%
FY2016Dec 31, 2016$166.50M+60.6%
FY2015Dec 31, 2015$103.70M+130.9%
FY2014Dec 31, 2014$44.91M+128.3%
FY2013Dec 31, 2013$19.67M–
FY2012Dec 31, 2012$0-100.0%
FY2011Dec 31, 2011$510.22K-60.5%
FY2010Dec 31, 2010$1.29M+15553.0%
FY2009Dec 31, 2009$8.26K+184.2%
FY2008Dec 31, 2008$2.91K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$297.67M-1.2%
Q1 FY2026Mar 31, 2026$313.44M-12.9%
Q4 FY2025Dec 31, 2025$296.98M-10.0%
Q3 FY2025Sep 30, 2025$300.80M-24.3%
Q2 FY2025Jun 30, 2025$301.18M-27.0%
Q1 FY2025Mar 31, 2025$359.71M+1.0%
Q4 FY2024Dec 31, 2024$330.14M+18.0%
Q3 FY2024Sep 30, 2024$397.49M+10.0%
Q2 FY2024Jun 30, 2024$412.54M+64.4%
Q1 FY2024Mar 31, 2024$356.20M-43.1%
Q4 FY2023Dec 31, 2023$279.87M-41.5%
Q3 FY2023Sep 30, 2023$361.37M+0.3%
Q2 FY2023Jun 30, 2023$250.89M-40.9%
Q1 FY2023Mar 31, 2023$626.29M+29.9%
Q4 FY2022Dec 31, 2022$478.28M-6.3%
Q3 FY2022Sep 30, 2022$360.17M-37.5%
Q2 FY2022Jun 30, 2022$424.46M-35.3%
Q1 FY2022Mar 31, 2022$482.19M-21.0%
Q4 FY2021Dec 31, 2021$510.49M-19.6%
Q3 FY2021Sep 30, 2021$576.45M-19.9%
Q2 FY2021Jun 30, 2021$656.37M-15.6%
Q1 FY2021Mar 31, 2021$610.20M+142.9%
Q4 FY2020Dec 31, 2020$635.00M+103.2%
Q3 FY2020Sep 30, 2020$719.70M+98.9%
Q2 FY2020Jun 30, 2020$777.40M+92.4%
Q1 FY2020Mar 31, 2020$251.20M-34.9%
Q4 FY2019Dec 31, 2019$312.53M-19.1%
Q3 FY2019Sep 30, 2019$361.90M+101.9%
Q2 FY2019Jun 30, 2019$404.10M+1243.3%
Q1 FY2019Mar 31, 2019$385.93M+29.9%
Q4 FY2018Dec 31, 2018$386.37M–
Q3 FY2018Sep 30, 2018$179.26M+9.7%
Q2 FY2018Jun 30, 2018$30.08M-76.7%
Q1 FY2018Mar 31, 2018$297.10M+101.8%
Q4 FY2017Dec 31, 2017$0-100.0%
Q3 FY2017Sep 30, 2017$163.40M-8.9%
Q2 FY2017Jun 30, 2017$129.00M–
Q1 FY2017Mar 31, 2017$147.20M–
Q4 FY2016Dec 31, 2016$166.50M–
Q3 FY2016Sep 30, 2016$179.30M–

More Iovance Biotherapeutics figures

See a number that looks wrong?